$64.11 meals Payment -- Merck & Co to Dr. Rachel Parker

Merck & Co. provides $64.11 in meals to an Infectious Disease physician for Rinvoq.

This page provides a detailed analysis of a $64.11 meals payment from Merck & Co to Dr. Rachel Parker. Data is from the CMS Open Payments (Sunshine Act) database.

Payment Details

FieldValue
Amount$64.11
Payment Typemeals
Payment NatureFood and Beverage
Pharmaceutical CompanyMerck & Co
PhysicianDr. Rachel Parker
NPI Number1720680941
Physician SpecialtyInfectious Disease
LocationAthens, GA
Date of Payment2026-01-29
Related Drug/DeviceRinvoq
Conflict AssessmentLow -- Routine

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Merck & Co made a $64.11 meals payment to Rachel Parker, a Infectious Disease specialist in Athens, GA. The payment was associated with Rinvoq. The payment of $64.11 from Merck & Co to Dr. Rachel Parker was for meals related to the drug Rinvoq. This payment occurred on January 29, 2026, in Athens, GA. The payment was categorized as 'Food and Beverage' under the 'meals' payment type.

Patient Guidance: What This Payment Means for You

This payment was for a meal provided by a pharmaceutical company, which is a common practice in the healthcare industry. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

For an Infectious Disease specialist, a $64.11 meal payment from a pharmaceutical company is generally considered a low-value transaction.

Regulatory Context: Sunshine Act Requirements

Payments for meals are reportable under the Sunshine Act, provided they meet certain criteria and are associated with a covered drug or device.

Related Topics

This payment is related to the following healthcare transparency topics:

Understanding meals Payments

Food and beverage payments cover meals provided to physicians during pharmaceutical sales representative visits, medical conferences, and educational events. While individual meal payments tend to be small (often under $100), research published in JAMA Internal Medicine has shown that even modest meals can be associated with changes in prescribing behavior. Meal payments are the most common type of pharmaceutical payment to physicians.

Frequently Asked Questions About This Payment

What was this $64.11 payment for?

This was a meals payment of $64.11 from Merck & Co to Rachel Parker, categorized as "Food and Beverage". It was associated with Rinvoq. The payment was reported under the Sunshine Act (CMS Open Payments).

Does Rachel Parker accept pharmaceutical money?

Yes, Rachel Parker received this $64.11 payment from Merck & Co. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Rachel Parker's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this meals payment?

A meals payment of $64.11 is generally routine and common in the industry. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Infectious Disease?

To compare this payment against Infectious Disease averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Infectious Disease physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Rachel Parker's relationship with Merck & Co?

The payment amount is relatively small, suggesting a minor interaction. This $64.11 meals payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Infectious Disease?

The payment is specifically linked to the drug Rinvoq.

What should patients do after learning about this payment?

This payment was for a meal provided by a pharmaceutical company, which is a common practice in the healthcare industry.

What else should I know about this meals payment?

The date of payment is in the future, indicating potential pre-planning or data entry lag.

Related Reports

Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.